[Oxiconazole cream versus ketoconazole cream. A prospective, randomized, double-blind, multicenter study in the treatment of inguinocrural dermatophytoses]. / Oxiconazole crème versus kétoconazole crème. Etude prospective, randomisée, en double insu, multicentrique, dans le traitement des dermatophytoses inguinocrurales.

INTRODUCTION: The aim of this study was to compare oxiconazole, 1 p. 100 cream, with ketoconazole, 2 p. 100 cream, applied once-daily, in the treatment of tinea cruris. PATIENTS AND METHODS: A prospective, randomized, double-blind trial was performed in 8 dermatology departments on two parallel groups in patients having this type of mycosis confirmed by mycological examination. RESULTS: The efficacy was analyzed in 66 out of the 79 patients included in the study (36 patients treated with oxiconazole, 30 with ketoconazole). At Day 14, a first assessment was made and 77.1 p. 100 of the patients treated with oxiconazole had been cured; this result was significantly better (p < 0.05) than that obtained with ketoconazole (51.7 p. 100 of cured patients). At Day 21, after a further week of treatment, both treatments were efficient with statistically non-different results between the two groups: 97.2 p. 100 of the patients treated with oxiconazole, versus 86.7 p. 100 with ketoconazole. Thus, a greater rapidity of action of oxiconazole was observed. No correlation was detected between the ratio of cured patients and the duration of the mycosis. The safety was assessed in 74 patients. No adverse effects were reported for the patients treated with oxiconazole, whereas 9 patients treated with ketoconazole experienced contact sensitization reactions and irritant skin reactions due to the application of the product. The difference between the two groups of treatment was statistically greatly significant (p < 0.001). Furthermore, acceptance of the drug on the part of the patient was better (p < 0.05) with oxiconazole. DISCUSSION: After 3 weeks of topical treatment oxiconazole has revealed itself to be as efficient as ketoconazole, but it seems more rapidly efficient and better tolerated than ketoconazole.

Dermatitis due to orthopaedic implants. A review of the literature and report of three cases.

The cases of three patients who had dermatosis that was caused by an orthopaedic implant are reported. The main clinical pattern was localized or generalized eczema or urticaria. The diagnostic criteria that have been proposed by various authors are reviewed. Removal of the implant did not always result in rapid disappearance of the dermatosis, presumably because a few particles of metal remained in the area of the implant.

[The association tretinoin-erythromycin base: a new topical treatment for acne. Results of a multicentric trial on 347 cases (authors transl)]. / L'association tretinoïne-erythromycine base: nouveau traitement local de l'acné. Etude multicentrique sur 347 cas.

A multicentric trial involving ten dermatological departments was conducted to evaluate the efficacy and tollerance of ANTIBIO-ABEREL (an association of Tretinoin and Erythromycin base) in 347 patients with persistant acne. Complete healing or considerable improvement was obtained in 85% of cases. This new treatment was active against both inflammatory lesions (papules and pustules) and retentional elements (microcysts and open comedones). It was also rapidly active, as very favorable results were obtained in ten weeks or less, in more than half of the cases. The tolerance was remarkable (less than 1% of cases had to interrupt treatment). This product represents an important progress as compared to Tretinoin alone. No other local or systemic therapy, especially long term antibiotherapy, is required.

[A controlled double-blind clinical trial of a new association of a wide-spectrum antifungal preparation and a corticoid (author's transl)]. / Essai thérapeutique controlé en double insu d'une nouvelle association d'un antifongique à large spectre et d'un corticoïde.

In a controlled double-blind study, the author has comparatively studied the effectiveness and the safety of econazole and of a combination econazole-triamcinolon topically applied, on inflammatory dermatomycoses. Results on 58 patients are reported. The respective well-known properties of econazole and of triamcinolon are maintained in the combination. Clinical symptoms statistically faster disappear with the combined preparation, during the first days of treatment. In addition, the average treatment duration is shortened when econazole-triamcinolon is applied. The new preparation allows security to the physician as well it makes the patient more comfortable.